Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Central Nervous System Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
52 drugs · 206 active trials
5 drugs · 33 active trials
5 drugs · 185 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Prednisolone | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Teniposide | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 1, 2025 |
| Sunitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 14 | 0 | — | — | 2006-09 |
| Imatinib Mesylate | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 2001-08 |
| Enzastaurin | Phase 3 | Phase 3 | 0 | 0 | 2 | 5 | 0 | — | — | 2002-10 |
| Hydroxyurea | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2004-10 |
| Chloroquine | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2005-01 |
| Clofarabine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Feb 29, 2012 |
| Dactinomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2009-11 |
| Radiation Therapy | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2001-02 |
| Tofacitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Oct 7, 2022 |
| Pemetrexed | Phase 2 | Phase 2 | 11 | 6 | 0 | 19 | 0 | — | — | 2007-09 |
| Fludarabine | Phase 2 | Phase 2 | 11 | 10 | 0 | 18 | 0 | — | — | 1999-11 |
| Ibrutinib | Phase 2 | Phase 2 | 8 | 4 | 0 | 15 | 0 | — | — | Aug 14, 2014 |
| Atezolizumab | Phase 2 | Phase 2 | 8 | 2 | 0 | 12 | 0 | — | — | Jun 15, 2017 |
| Lenalidomide | Phase 2 | Phase 2 | 6 | 4 | 0 | 18 | 0 | — | — | 2004-11 |
| Olaparib | Phase 2 | Phase 2 | 6 | 1 | 0 | 8 | 0 | — | — | Jul 31, 2017 |
| Retifanlimab | Phase 2 | Phase 2 | 5 | 3 | 0 | 6 | 0 | — | — | Apr 20, 2020 |
| Acalabrutinib | Phase 2 | Phase 2 | 5 | 1 | 0 | 5 | 0 | — | — | Jan 25, 2016 |
| Selinexor | Phase 2 | Phase 2 | 4 | 3 | 0 | 8 | 0 | — | — | Mar 3, 2014 |
| Sintilimab | Phase 2 | Phase 2 | 4 | 4 | 0 | 6 | 0 | — | — | Jun 1, 2020 |
| Abemaciclib | Phase 2 | Phase 2 | 3 | 2 | 0 | 7 | 0 | — | — | 2016-02 |
| Palbociclib | Phase 2 | Phase 2 | 3 | 1 | 0 | 7 | 0 | — | — | 2010-09 |
| Cemiplimab | Phase 2 | Phase 2 | 3 | 0 | 0 | 6 | 0 | — | — | May 31, 2018 |
| Zanubrutinib | Phase 2 | Phase 2 | 3 | 3 | 0 | 6 | 0 | — | — | Aug 1, 2020 |
| Pegfilgrastim | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | Jun 19, 2013 |
| Erdafitinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Jul 31, 2017 |
| Larotrectinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Jul 31, 2017 |
| Tipifarnib | Phase 2 | Phase 2 | 2 | 0 | 0 | 9 | 0 | — | — | 2002-09 |
| Gemcitabine | Phase 2 | Phase 2 | 2 | 1 | 0 | 8 | 0 | — | — | 2006-06 |
| Ribociclib | Phase 2 | Phase 2 | 2 | 1 | 0 | 8 | 0 | — | — | 2016-03 |
| Pomalidomide | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | Apr 8, 2013 |
| Obinutuzumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | May 12, 2020 |
| Tazemetostat | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | Dec 22, 2015 |
| Ensartinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Epcoritamab | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Aug 13, 2025 |
| Ivosidenib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Lutetium (177lu) Oxodotreotide | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Apr 14, 2020 |
| Selpercatinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Tamoxifen | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Jan 28, 2022 |
| Bortezomib | Phase 2 | Phase 2 | 1 | 0 | 0 | 8 | 0 | — | — | 2001-05 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 8 | 0 | — | — | 2009-01 |
| Capecitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2003-09 |
| Pazopanib | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | 2007-05 |
| Valproic Acid | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2006-03 |
| Aminolevulinic Acid | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2009-09 |
| Afatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | Sep 17, 2009 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2008-05 |
| Celecoxib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2003-09 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.